BZ (3-quinuclidinyl benzilate)
GPTKB entity
Statements (37)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
deliriant incapacitating agent |
| gptkbp:antidote |
gptkb:physostigmine
|
| gptkbp:appearance |
white crystalline solid
|
| gptkbp:CASNumber |
6581-06-2
|
| gptkbp:category |
anticholinergic deliriant
deliriant chemical weapon quinuclidine derivative |
| gptkbp:chemicalFormula |
C21H23NO3
|
| gptkbp:developedBy |
gptkb:United_States_military
|
| gptkbp:effect |
confusion
disorientation blurred vision hallucinations dry mouth |
| gptkbp:firstSynthesized |
1951
|
| https://www.w3.org/2000/01/rdf-schema#label |
BZ (3-quinuclidinyl benzilate)
|
| gptkbp:IUPACName |
1-azabicyclo[2.2.2]octan-3-yl 2-hydroxy-2,2-diphenylacetate
|
| gptkbp:legalStatus |
Schedule 2 (Chemical Weapons Convention)
|
| gptkbp:mechanismOfAction |
anticholinergic
|
| gptkbp:meltingPoint |
165–166 °C
|
| gptkbp:molecularWeight |
337.41 g/mol
|
| gptkbp:PubChem_CID |
10241
CHEMBL2104126 |
| gptkbp:relatedTo |
scopolamine
atropine |
| gptkbp:routeOfExposure |
inhalation
skin contact |
| gptkbp:solubility |
slightly soluble in water
|
| gptkbp:toxicity |
high
|
| gptkbp:UNII |
8VZV102JFY
|
| gptkbp:used_in |
gptkb:Operation_DORK
Edgewood Arsenal experiments |
| gptkbp:usedFor |
chemical weapon
|
| gptkbp:bfsParent |
gptkb:Edgewood_Arsenal_human_experiments
|
| gptkbp:bfsLayer |
7
|